Acceleron Pharma Inc.
ALK7 BINDING PROTEINS AND USES THEREOF

Last updated:

Abstract:

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

Status:
Application
Type:

Utility

Filling date:

25 Oct 2018

Issue date:

17 Dec 2020